Sandoz Group AG

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Sandoz Group AG engages in focusing on generic pharmaceuticals and bio similar medical products. It acquires, manages and sells investments and intellectual property in the healthcare and medical device industry and conducts all business at home and abroad. The firm can acquire, sell, debit and manage interests in other companies, intellectual property rights and real estate at home and abroad, as well as establish branches and subsidiaries at home and abroad. The company was founded on January 17, 2022 and is headquartered in Rotkreuz, Switzerland.

Zoetis

Investors looking for stocks in the Medical - Drugs sector might want to consider either Sandoz Group AG Sponsored ADR (SDZNY) or Zoetis (ZTS). But which of these two stocks offers value investors a better bang for their buck right now?

SDZNY or ZTS: Which Is the Better Value Stock Right Now?

Sandoz Group AG Sponsored ADR (SDZNY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Sandoz Group AG Sponsored ADR (SDZNY) Upgraded to Strong Buy: Here's What You Should Know

Sandoz Group AG Sponsored ADR (SDZNY) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Here's Why Sandoz Group AG Sponsored ADR (SDZNY) Is a Great 'Buy the Bottom' Stock Now

Investors looking for stocks in the Medical - Drugs sector might want to consider either Sandoz Group AG Sponsored ADR (SDZNY) or Zoetis (ZTS). But which of these two companies is the best option for those looking for undervalued stocks?

SDZNY vs. ZTS: Which Stock Is the Better Value Option?

Investors with an interest in Medical - Drugs stocks have likely encountered both Sandoz Group AG Sponsored ADR (SDZNY) and Zoetis (ZTS). But which of these two stocks offers value investors a better bang for their buck right now?

SDZNY vs. ZTS: Which Stock Should Value Investors Buy Now?

ANTWERP, Belgium--(BUSINESS WIRE)--Agomab Therapeutics NV (‘Agomab') today announced the appointment of Colin Bond to the company's Board of Directors as a non-executive Director and Chairman of the Audit Committee. With an extensive career in finance that spans over three decades at leading international corporations, Colin also brings fifteen years of experience as a CFO at listed biopharmaceutical companies in Switzerland, Germany and the US. “We welcome Colin to our Board of Directors,” sai.

Agomab Announces the Appointment of Former Sandoz CFO Colin Bond to its Board of Directors

MEDIA RELEASE Afqlir® (aflibercept) approved to treat various retinal diseases, including neovascular age-related macular degeneration (nAMD) One of several biosimilar value drivers for Sandoz Sandoz remains committed to accelerating patient access by strengthening its biosimilar portfolio, reinforcing global and European leadership Basel, November 15, 2024 – Sandoz (SIX:SDZ/OTCQX:SDZNY), the global leader in generic and biosimilar medicines, today announced that the European Commission (EC) has granted marketing authorization for Afqlir® (aflibercept) 2 mg vial kit and pre-filled syringe for intravitreal injection, a biosimilar to reference medicine Eylea®*[1,2]. Afqlir® is indicated to treat various retinal diseases, including neovascular age-related macular degeneration (nAMD), aiming to prevent disease-related blindness.

Sandoz receives European Commission approval for Afqlir® (aflibercept), further strengthening leading biosimilar portfolio

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Strong third-quarter biosimilars growth of 37% in constant currencies from existing portfolio and recent launches Generics growth acceleration driven by Europe Third-quarter net sales¹ of USD 2.6 billion, up 12% in constant currencies (up 11% in USD) Nine-month net sales of USD 7.6 billion, up 9% in constant currencies (up 8% in USD) Net sales growth guidance increased to high-single digit in constant currencies (from mid- to high-single digit) and core EBITDA margin² guidance of around 20% confirmed Basel, October 30, 2024 – Sandoz (SIX:SDZ/OTCQX:SDZNY), the global leader in generic and biosimilar medicines, today announced net sales for the third quarter and nine months ended September 30, 2024.

Sandoz reports third-quarter and nine-month 2024 sales

MEDIA RELEASE First FDA-approved abbreviated new drug application (ANDA) to reference medicine Single-dose 100 mg vial for intravenous use, approved for metastatic breast cancer Launch expected to be near-term growth driver in US market Princeton, NJ, October 11, 2024 – Sandoz, the global leader in generic and biosimilar medicines, today announced that it has launched a generic paclitaxel formulation in the US, the first generic to its reference medicine to be approved by the US Food and Drug Administration (FDA). Sandoz paclitaxel protein-bound particles for injectable suspension (albumin-bound) is indicated for the treatment of patients with metastatic breast cancer.

Sandoz US launches generic paclitaxel in single-dose vial, further expanding US oncology portfolio

BOUCHERVILLE, Quebec, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Sandoz Canada obtained carbon neutral certification from the engineering consulting firm LCL Engineering, Environment & Sustainable Development for its Boucherville head office and business travel activities. This certification attests to the company's commitment to being an environmentally conscious leader in the generics and biosimilars market by striving to keep people and the planet healthy. In addition to obtaining the certification, Sandoz Canada recently took part in the Mission 1000 tonnes initiative for the second year in a row and switched to eco-friendly Forest Stewardship Council (FSC)–certified packaging for its injectable medicines. Carbon neutral certification To better understand the environmental impact of its domestic activities, Sandoz Canada teamed up with LCL Engineering, Environment & Sustainable Development. This Quebec-based environmental consulting firm made a comprehensive inventory of the company's CO2 emissions using a rigorous process based on the ISO 14064-1 standard. The calculation included a wide range of sources, such as head office electricity consumption, refrigerant purchases, company car mileage and travel ticket purchases. Emissions linked to the manufacturing and transportation of medicines were not taken into account.

Sandoz Canada achieves carbon neutral certification for its commercial operations

Stevanato Group SpA

Investors with an interest in Medical - Drugs stocks have likely encountered both Sandoz Group AG Sponsored ADR (SDZNY) and Stevanato Group (STVN). But which of these two companies is the best option for those looking for undervalued stocks?

SDZNY vs. STVN: Which Stock Is the Better Value Option?

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Enzeevu™ (aflibercept-abzv) approved to treat neovascular age-related macular degeneration Further enhances leading US ophthalmology portfolio and increases access for patients Expected to be key biosimilar growth driver in US Basel, August 12, 2024 – Sandoz (SIX:SDZ/OTCQX:SDZNY), the global leader in generic and biosimilar medicines, today announced that the US Food and Drug Administration (FDA) has approved Enzeevu™ (aflibercept-abzv) 2 mg vial kit and pre-filled syringe for intravitreal injection.

Sandoz receives FDA approval for Enzeevu™ (aflibercept-abzv), further strengthening US biosimilar position

Sandoz Group AG (OTCQX:SDZNY) Q2 2024 Earnings Conference Call August 8, 2024 3:00 AM ET Company Participants Karen King - Global Head, Investor Relations Richard Saynor - Chief Executive Officer Remco Steenbergen - Chief Financial Officer Conference Call Participants James Gordon - JPMorgan Harry Sephton - UBS Victor Floch - BNP Paribas Exane Simon Baker - Redburn Atlantic Emily Field - Barclays Graham Parry - Bank of America Nicolas Pauillac - Kepler Cheuvreux Thibault Boutherin - Morgan Stanley James Vane-Tempest - Jefferies Victoria Lambert - Berenberg Operator Good morning, ladies and gentlemen and welcome to the Sandoz call today. I will now pass on to Karen King, Global Head of Investor Relations for her opening remarks.

Sandoz Group AG (SDZNY) Q2 2024 Earnings Call Transcript

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Strong double-digit growth in biosimilars of 29% from existing portfolio and recent launches Second-quarter net sales[1] of USD 2.6 billion, up 9% in constant currencies (up 7% in USD) Half-year net sales of USD 5.0 billion, up 7% in constant currencies (up 6% in USD) Half-year core EBITDA margin[2] of 17.5%, a strong 210 basis point improvement versus H2 2023, driven by favorable biosimilars mix; within H1, margin expanded quarter-over-quarter Half-year 2024 EBITDA margin of 11.4%, due to one-time separation and transformation costs, and rationalization of specific manufacturing sites Net sales growth guidance increased to mid- to high-single digit in constant currencies (from mid-single digit) and reinforced confidence in core EBITDA margin of around 20% Executive Committee appointments: Rebecca Guntern as Chief Commercial Officer, and Christophe Delenta as President Europe, both effective September 1, 2024 Basel, August 8, 2024 – Sandoz (SIX:SDZ/OTCQX:SDZNY), the global leader in generic and biosimilar medicines, today announced net sales for the second quarter and results for the half year ended June 30, 2024.

Sandoz reports second-quarter sales and half-year 2024 results

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Sandoz launches biosimilar Pyzchiva® (ustekinumab) across Europe, to treat chronic inflammatory diseases Launch across Europe, starting today, strengthens well-established Sandoz immunology portfolio in Europe, leveraging existing footprint Pyzchiva® first ustekinumab biosimilar to launch in Europe with all reference medicine strengths, including 130mg vial initiation dose for Crohn's disease Pyzchiva® to treat adults with plaque psoriasis, psoriatic arthritis, Crohn's disease and pediatric plaque psoriasis Basel, July 25, 2024 – Sandoz, the global leader in generic and biosimilar medicines, announces the launch of Pyzchiva®* (ustekinumab) across Europe, starting today.

Sandoz launches biosimilar Pyzchiva® (ustekinumab) across Europe, to treat chronic inflammatory diseases

GRAIL Inc

WK Kellogg Co

Stock spinoffs remain popular with companies wanting to unlock shareholder value. By creating spinoff stocks that will trade independently on the market, corporations believe they can narrow their focus to core operations while the newly public company doesn't get lost in the shuffle of its parent's larger objectives.

3 Spinoff Stocks You Should Buy Now: July 2024

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules FDA approves biosimilar Pyzchiva® (ustekinumab-ttwe), to be commercialized by Sandoz in US Pyzchiva® (ustekinumab-ttwe) is approved by FDA for all indications of reference medicine FDA granted provisional determination for interchangeability designation for Pyzchiva® Extends Sandoz immunology portfolio and further strengthens biosimilar position Expected to be among first wave of ustekinumab biosimilars to launch in US Basel, July 1, 2024 – Sandoz, the global leader in generic and biosimilar medicines, today announced that the US Food and Drug Administration (FDA) has approved biosimilar Pyzchiva®* (ustekinumab-ttwe) 45 mg/0.5 mL and 90 mg/mL pre-filled syringes for subcutaneous injection and 130 mg/26 mL (5 mg/mL) single-dose vial for intravenous infusion.

FDA approves biosimilar Pyzchiva® (ustekinumab-ttwe), to be commercialized by Sandoz in US

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Wyost® (denosumab) and Jubbonti® (denosumab) approved by EC for all indications of denosumab reference medicines Xgeva® and Prolia® EC approval based on robust development program confirming that biosimilar matches reference medicine in terms of safety, efficacy and quality Approved for treatment of cancer-related bone disease and osteoporosis respectively Basel, May 22, 2024 – Sandoz, the global leader in generic and biosimilar medicines, today announced that the European Commission (EC) has granted marketing authorization for Wyost®1 (denosumab) and Jubbonti®2 (denosumab), the first and only biosimilar versions of reference medicines Xgeva®*3 and Prolia®*4 in Europe.

Sandoz receives European Commission approval for Wyost® and Jubbonti®, the first and only biosimilars of denosumab in Europe

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Strong first quarter performance, with net sales [1] of USD 2.5 billion, up 6% in constant currencies (up 5% in USD) Biosimilar business growing 21% in constant currencies  All regions contributing to growth Acquisition of CIMERLI® (ranibizumab-eqrn) completed in March 2024 Basel, May 7, 2024 – Sandoz (SIX:SDZ/OTCQX:SDZNY), the global leader in generic and biosimilar medicines, today announced net sales for the first quarter 2024.

Sandoz reports first quarter 2024 sales

All proposals of Board of Directors approved Gilbert Ghostine re-elected as Chairman of Board of Directors; all other Board members standing for election confirmed Mathai Mammen, Graeme Pitkethly and Michael Rechsteiner elected as new Board members Dividend of CHF 0.45 per registered dividend-paying share approved, representing 24% of core net income Basel, April 30, 2024 – Sandoz (SIX: SDZ; OTCQX: SDZNY) today announced that its shareholders approved all proposals of the Board of Directors at its Annual General Meeting, including the Annual Financial Statements and Consolidated Financial Statements as well as the report on non-financial matters for the 2023 financial year. The shareholders in attendance, together with the votes represented by the independent proxy, represented 79.23% of registered shares.

Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AG

Amgen

Swiss generic and biosimilar manufacturer Sandoz said on Tuesday it had reached an agreement with U.S. drugmaker Amgen resolving all patent litigation related to its U.S. denosumab biosimilars.

Sandoz reaches agreement with Amgen over patent dispute

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab biosimilars Agreement clears path for launch of Jubbonti® and Wyost® on May 31, 2025 or earlier under certain circumstances Jubbonti® and Wyost® are first and only FDA-approved biosimilars to and interchangeable with Prolia*® and Xgeva*® Anticipated launch further strengthens Sandoz biosimilar portfolio and advances growth strategy Basel, April 30, 2024 – Sandoz, the global leader in generic and biosimilar medicines, today announced that it has reached agreement with Amgen to resolve all patent disputes between the two companies relating to the US Food and Drug Administration (FDA)-approved Sandoz denosumab biosimilars.

Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab biosimilars

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Pyzchiva® approved as one of first ustekinumab biosimilars in Europe EC approval based on robust development program confirming match to reference medicine in terms of safety, efficacy and quality Sandoz remains committed to accelerating access to potentially life-changing treatments and continues strengthening immunology portfolio Basel, April 22, 2024 – Sandoz, the global leader in generic and biosimilar medicines, today announces that the European Commission (EC) has granted marketing authorization for Pyzchiva®* (biosimilar ustekinumab), developed and registered by Samsung Bioepis.

Sandoz confirms European Commission approval of Pyzchiva® (ustekinumab), further strengthening immunology offering

MEDIA RELEASE EUR 50m investment in Kundl plant extension emphasizes commitment to serve more patients with critical antibiotics, produced entirely in Europe Additional manufacturing area of 3,000m2 means Kundl can now manufacture 240 million packages per year Represents capacity increase of 20% over 2023 and more than doubling from 2021 output levels Automation and innovative technologies allow production of one billion more penicillin tablets and doubling of output for key pediatric formulation Latest investment follows commissioning of EUR 150m antibiotic active ingredient facility -- on stream since November 2023 Basel, March 21, 2024 – Sandoz, the global leader in generic and biosimilar medicines, today opened a new production facility in Kundl, Austria, to serve more patients with affordable life-saving drugs produced entirely in Europe. The new facility and automated production lines will increase production capacity by 20% compared to the current capacity of 200 million packages per year.

Sandoz opens new antibiotic production facility in Austria, to significantly increase capacity for life-saving medicines

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Strong fourth quarter performance, with net sales1 of USD 2.5 billion, up 10% in constant currencies (up 11% in USD) Full-year 2023 net sales of USD 9.6 billion, up 7% in constant currencies (up 6% in USD) Strong growth across all three regions and double-digit growth in biosimilars both in the fourth quarter and full year Full-year 2023 core EBITDA margin of 18.1%, with strong contribution from net sales offset by expected inflation and standalone costs, and foreign exchange headwinds of 1.7 percentage points Full-year 2023 EBITDA margin of 9.5%, due to legal settlements, one-time separation costs and rationalization of specific manufacturing sites 2024 guidance of mid-single digit net sales growth in constant currencies and core EBITDA margin around 20% Basel, March 13, 2024 – Sandoz (SIX:SDZ/OTCQX:SDZNY), the global leader in generic and biosimilar medicines, today announced net sales for the fourth quarter and results for the full year ended December 31, 2023.

News for Sandoz Group AG Stock (SDZNY)